Advancing cervical cancer prevention in India: Implementation science priorities

Oncologist

Volumn 18, Issue 12, 2013, Pages 1285-1297

  Krishnan, Suneeta ^a,b   Madsen, Emily ^a   Porterfield, Deborah ^a,c   Varghese, Beena ^b,d  

^a RTI INTERNATIONAL   (United States)

^b ST JOHN'S NATIONAL ACADEMY OF HEALTH SCIENCES   (India)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d PUBLIC HEALTH FOUNDATION OF INDIA   (India)

Author keywords

Cancer screening; Cervical cancer; HPV vaccines; India

Indexed keywords

ACETIC ACID; WART VIRUS VACCINE; LUGOL;

ARTICLE; CANCER PREVENTION; CANCER RESEARCH; CANCER SCREENING; COMMUNITY ASSESSMENT; COST BENEFIT ANALYSIS; DIAGNOSTIC ACCURACY; HEALTH CARE PERSONNEL; HEALTH CARE PLANNING; HEALTH CARE QUALITY; HUMAN; INDIA; MORTALITY; MULTICENTER STUDY (TOPIC); PRIMARY PREVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SECONDARY PREVENTION; UTERINE CERVIX CANCER; VACCINATION; BIOPSY; CANCER MORTALITY; COLPOSCOPY; CONTROL STRATEGY; COST EFFECTIVENESS ANALYSIS; COUNSELING; CRYOTHERAPY; FEMALE; HUMAN PAPILLOMAVIRUS DNA TEST; MEDICAL PERSONNEL; MORBIDITY; PAPANICOLAOU TEST; PUBLIC HEALTH; QUALITY CONTROL; SENSITIVITY AND SPECIFICITY; TRAINING; WART VIRUS;

CANCER SCREENING; CERVICAL CANCER; HPV VACCINES; INDIA;

BIOMEDICAL RESEARCH; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; INDIA; MASS SCREENING; PAPILLOMAVIRUS VACCINES; UTERINE CERVICAL NEOPLASMS; VACCINATION; ADULT; AGED; EARLY DETECTION OF CANCER; HEALTH PRIORITIES; MIDDLE AGED; PAPILLOMAVIRUS INFECTIONS;

EID: 84890017767     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2013-0292     Document Type: Article

References (58)

1. Institute for Health Metrics and Evaluation. The challenge ahead: Progress in breast and cervical cancer. Institute of Health Metrics and Evaluation, 2011. Available at http://www.healthmetricsandevaluation.org/publications/policyreport/challenge-ahead-progress-and-setbacks-breast-and-cervical-cancer. Accessed July 2, 2013.
2. Nandakumar A, Anantha N, Venugopal TC. Incidence, mortality and survival in cancer of the cervix in Bangalore, India Br J Cancer 1995;71:1348-1352.
3. Vallikad E. Cervical cancer: The Indian perspective. Int J Gynaecol Obstet 2006;95(suppl 1):215-233.
4. Jacob M. Assessing the environment for introduction of human papillomavirus vaccine in India. Open Vaccine J 2010;3:96-107.
5. Madhivanan P, Krupp K, Yashodha MN et al. Attitudes toward HPV vaccination among parents of adolescent girls in Mysore, India Vaccine 2009;27: 5203-5208.
6. World Health Organization. Weekly epidemiological record. WHO, 2009. Available at http://www.who.int/wer/2009/wer8415.pdf. Accessed January 14, 2013.
7. Singh A, Datta P, Jain SK et al. Human papilloma virus genotyping, variants and viral load in tumors, squamous intraepithelial lesions, and controls in a North Indian population subset. Int J Gynaecol Cancer 2009;19:1642-1648.
8. Sowjanya AP, Jain M, Poli UR et al. Prevalence and distribution of high-risk human papilloma virus (HPV) types in invasive squamous cell carcinoma of the cervix and in normal women in Andhra Pradesh, India BMC Infect Dis 2005;5:116.
9. PATH. Update: Path's HPV vaccine project in India. Available at: http://www.path.org/news/press-room/333/. Accessed October 11, 2013.
10. Rathod SD. Commentary on HPV screening for cervical cancer in rural India. Ind J Med Ethics 2011; 8:180-182.
11. Srinivasan S. HPV vaccine trials and sleeping watchdogs. Ind J Med Ethics 2011;8:73-74.
12. Kang G. HPV vaccines: Separating real hope from drug company hype. Ind J Med Ethics 2010;7: 56-57.
13. Ramanathan M, Varghese J. The HPV vaccine demonstration projects: We should wait, watch and learn. Ind J Med Ethics 2010;7:43-45.
14. Dabade G, Abhiyan JS, Madhavi Y et al. Concerns around the human papilloma virus (HPV) vaccine. Ind J Med Ethics 2010;7:38-41.
15. Mattheji I, Pollock A, Brhlikova P. Do cervical cancer data justify HPV vaccination in India? Epidemiological data sources and comprehensiveness. JR Soc Med 2012;105:250-262.
16. Mudur G. Human papillomavirus vaccine project stirs controversy in India. BMJ 2010;340:c1775.
17. Mudur G. Row erupts over study of HPV vaccine in 23 148 000 girls in India. BMJ 2012;345: e4930.
18. Tsu V. Should the ideal be the enemy of the good? JR Soc Med 2012;105:366.
19. Diaz M, Kim JJ, Albero G et al. Health and economic impact of HPV 16 and 18 vaccination and cervical cancer screening in India. Br J Cancer 2008;99: 230-238.
20. Alliance G. Human papillomavirus vaccine support. 2013. Available at: http://www.gavialliance.org/support/nvs/human-papillomavirus-vaccinesupport/. Accessed July 2, 2013.
21. World Health Organization. WHO guidance note: Comprehensive cervical cancer prevention and control: A healthier future for girls and women. 2013. Available at: http://apps.who.int/iris/bitstream/10665/78128/3/9789241505147_eng.pdf. Accessed July 3, 2013.
22. Saxena U, Sauvaget C, Sankaranarayanan R. Evidence-based screening, early diagnosis and treatment strategy of cervical cancer for national policy in lowresource countries: Example of India. Asian Pac J Cancer Prev 2012;13:1699-1703.
23. Basu P, Sankaranarayanan SR, Mandal R et al. Visual inspection with acetic acid and cytology in the early detection of cervical neoplasia in Kolkata, India Int J Gynaecol Cancer 2003;13:626-632.
24. Bhatla N, Mukhopadhyay A, Kriplani A et al. Evaluation of adjunctive tests for cervical cancer screening in low resource settings. Ind J Cancer 2007;44:51-55.
25. Bhatla N, Gulati A, Mathur SR et al. Evaluation of cervical screening in rural North India. Int J Gynaecol Obstet 2009;105:145-149.
26. Bhatla N, Puri K, Kriplani A et al. Adjunctive testing for cervical cancer screening in low resource settings. Austr NZ J Obstet Gynaecol 2012;52:133-139.
27. Deodhar K, Sankaranarayanan R, Jayant K et al. Accuracy of concurrent visual and cytology screening in detecting cervical cancer precursors in rural India. Int J Cancer 2012;131:E954-62.
28. Ghosh P, Gandhi G, Kochhar PK et al. Visual inspection of cervix with lugol's iodine for early detection of premalignant and malignant lesions of cervix. Ind J Med Res 2012;136:265-271.
29. Gravitt PE, Paul P, Katki HA et al. Effectiveness of via, pap, and HPV DNA testing in a cervical cancer screening program in a peri-urban community in Andhra Pradesh, India PloS One 2010;5:e13711.
30. Sankaranarayanan R, Shastri SS, Basu P et al. The role of low-level magnification in visual inspection with acetic acid for the early detection of cervical neo plasia. Cancer Detect Prev 2004;28:345-351.
31. Sankaranarayanan R, Chatterji R, Shastri SS et al. Accuracy of human papillomavirus testing in primary screening of cervical neoplasia: Results from a multicenter study in India. Int J Cancer 2004;112: 341-347.
32. Sodhani P, Gupta S, Sharma JK et al. Test characteristics of various screening modalities for cervical cancer: A feasibility study to develop an alternative strategy for resource-limited settings. Cytopathology 2006;17:348-352.
33. Sankaranarayanan R, Rajkumar R, Theresa R et al. Initial results from a randomized trial of cervical visual screening in rural South India. Int J Cancer 2004;109:461-467.
34. Shastri S, Mittra I, Mishra G et al. Effect of visual inspection with acetic acid (via) screening by primary health workers on cervical cancer mortality: A cluster randomized controlled trial in Mumbai, India. J Clin Oncol 2013;31(suppl):abstr 2.
35. Sankaranarayanan R, Basu P, Wesley RS et al. Accuracy of visual screening for cervical neoplasia: Results from an IARC multicentre study in India and Africa. Int J Cancer 2004;110:907-913.
36. Sankaranarayanan R, Nene BM, Dinshaw KA et al. A cluster randomized controlled trial of visual, cytology and human papillomavirus screening for cancer of the cervix in rural India. Int J Cancer 2005;116: 617-623.
37. Sankaranarayanan R, Esmy PO, Rajkumar R et al. Effect of visual screening on cervical cancer incidence and mortality in Tamil Nadu, India: A clusterrandomised trial Lancet 2007;370:398-406.
38. Sankaranarayanan R, Nene BM, Shastri SS et al. HPV screening for cervical cancer in rural India. N Engl J Med 2009;360:1385-1394.
39. Sankaranarayanan R, Nessa A, Esmy PO et al. Visual inspection methods for cervical cancer prevention. Best Pract Res Clin Obstet Gynaecol 2012; 26:221-232.
40. Sankaranarayanan R. See-and-treat works for cervical cancer prevention: What about controlling the high burden in India? Indian J Med Res 2012; 135:576-579.
41. Chamot E, Kristensen S, Stringer JS et al. Are treatments for cervical precancerous lesions in lessdeveloped countries safe enough to promote scaling-up of cervical screening programs? A systematic review. BMC Women's Health 2010;10:11.
42. Szarewski A. Cervical screening by visual inspection with acetic acid. Lancet 2007;370:265-366.
43. Basu M. The relevance of cervical cancer screening and the future of cervical cancer control in India in the light of the approval of the vaccine against cervical cancer. Indian J Cancer 2006;43: 139.
44. Blumenthal PD, Lauterbach M, Sellors JW et al. Training for cervical cancer prevention programs in low-resource settings: Focus on visual inspection with acetic acid and cryotherapy. Int J Gynaecol Obstet 2005;89 (suppl 2):S30-37.
45. Austin RM, Zhao C. Test group biases and ethical concerns mar New England Journal of Medicine articles promoting HPV screening for cervical cancer in rural India. Cytojournal 2009;6:12.
46. Goldie SJ, Gaffikin L, Goldhaber-Fiebert JD et al. Cost-effectiveness of cervical-cancer screening in five developing countries. N Engl J Med 2005;353: 2158-2168.
47. Legood R, Gray AM, Mahe C et al. Screening for cervical cancer in India: How much will it cost? A trial based analysis of the cost per case detected Int J Cancer 2005;117:981-987.
48. Tamil Nadu Health Systems Project. Prevention and care for women: Cervical cancer screening pilot program. Available at: http://www.tnhsp.org/files/Cervical%20Cancer.pdf. Accessed October 14, 2013.
49. Basu P, Nessa A, Majid M et al. Evaluation of the national cervical cancer screening programme of Bangladesh and the formulation of quality assurance guidelines. J Fam Plann Reprod Health Care 2010;36:131-134.
50. Moon TD, Silva-Matos C, Cordoso A et al. Implementation of cervical cancer screening using visual inspection with acetic acid in rural Mozambique: Successes and challenges using HIV care and treatment programme investments in Zambézia Province. J Int AIDS Soc 2012;15:17406.
51. Mwanahamuntu MHS, Kapambwe VV, Pfaendler S et al. Advancing cervical cancer prevention initiatives in resource-constrained settings: Insights from the cervical cancer prevention program in Zambia. PLOS Med 2011;8:e1001032.
52. Agurto I, Sandoval J, De La Rosa M et al. Improving cervical cancer prevention in a developing country. Int J Qual Health Care 2006;18:81-86.
53. Rubenstein LV, Pugh J. Strategies for promoting organizational and practice change by advancing implementation research. J Gen Intern Med 2006;21 (suppl 2):S58-64.
54. Padian NS, Holmes CB, McCoy SI et al. Implementation science for the US president's emergency plan for aids relief (pepfar). JAIDS 2011;56: 199-203.
55. Denny L, Quinn M, Sankaranarayanan R. Chapter 8: Screening for cervical cancer in developing countries. Vaccine 2006;24 (suppl 3):71-77.
56. World Health Organization. Cervical cancer screening in developing countries: Report of a WHO consultation. 2002. Available at: http://whqlibdoc.who.int/publications/2002/9241545720.pdf. Accessed October 14,2013.
57. Bradley J, Coffey P, Arrossi S et al. Women's perspectives on cervical screening and treatment in developing countries: Experiences with new technologies and service delivery strategies. Women Health 2006;43:103-121.
58. Nene B, Jayant K, Arrossi S et al. Determinants of womens participation in cervical cancer screening trial, Maharashtra, India Bull World Health Org 2007;85:264-272.